Helen Won

Memorial Sloan Kettering Cancer Center - Center for Molecular Oncology

United States

SCHOLARLY PAPERS

2

DOWNLOADS

26

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (2)

1.

TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors

CELL-D-19-03416
Number of pages: 51 Posted: 17 Dec 2019
Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center - Cancer Biology and Genetics Program, Agency for Science, Technology and Research (A*STAR) - Bioinformatics Institute, Memorial Sloan Kettering Cancer Center - Department of Medicine, Memorial Sloan Kettering Cancer Center - Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center - Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program, University of Torino - Department of Oncology, FPO-IRCCS - Candiolo Cancer Institute, Memorial Sloan Kettering Cancer Center - Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program, H. Lee Moffitt Cancer Center and Research Institute - Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute - Department of Drug Discovery, University of Torino - Department of Oncology, Memorial Sloan Kettering Cancer Center - Department of Pathology, Memorial Sloan Kettering Cancer Center - Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center - Department of Medicine, Agency for Science, Technology and Research (A*STAR) - Bioinformatics Institute, Memorial Sloan Kettering Cancer Center - Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center - Department of Medicine and Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program
Downloads 15 (577,579)

Abstract:

Loading...

drug resistance, tyrosine kinase inhibitors, cancer, signaling

2.

Hyperactivation of Torc1 Drives Resistance to the Pan-Her Tyrosine Kinase Inhibitor Neratinib in Her2-Mutant Cancers

Number of pages: 43 Posted: 29 Mar 2019 Last Revised: 29 May 2019
UTSW Simmons Comprehensive Cancer Center, Vanderbilt University - Department of Medicine, Memorial Sloan Kettering Cancer Center - Center for Molecular Oncology, Vanderbilt University - Breast Cancer Program, UTSW Simmons Comprehensive Cancer Center, UTSW Simmons Comprehensive Cancer Center, Vanderbilt University - Department of Medicine, University of New Mexico - Comprehensive Cancer Center, Vanderbilt University - Center for Quantitative Sciences, University of Texas at Dallas - Howard Hughes Medical Institute, Vanderbilt University - Department of Medicine, Vanderbilt University - Department of Medicine, Puma Biotechnology Inc., Puma Biotechnology Inc., Puma Biotechnology Inc., Puma Biotechnology Inc., UTSW Simmons Comprehensive Cancer Center and UTSW Simmons Comprehensive Cancer Center
Downloads 11 (603,970)

Abstract:

Loading...